API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Under the acquisition, Essential Pharma has acquired rights to Reminyl (galantamine hydrobromide), a cholinesterase inhibitor, oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America.
Lead Product(s): Galantamine Hydrobromide
Therapeutic Area: Neurology Product Name: Reminyl
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 17, 2024